Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06891456 · ClinicalTrials.gov registry record · NA

Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia

A NA study of Ventricular Tachycardia and Ischemic Heart Disease, sponsored by Pasquale Santangeli.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06891456: Recruiting NA study of Ventricular Tachycardia and Ischemic Heart Disease, sponsored by Pasquale Santangeli.

NCT06891456 is a NA study of Ventricular Tachycardia and Ischemic Heart Disease that is actively recruiting participants, run by Pasquale Santangeli. The registered enrollment target is 40 participants, below the 287-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06891456, a NA study of Ventricular Tachycardia and Ischemic Heart Disease, is actively recruiting participants, sponsored by Pasquale Santangeli.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.

Primary Outcome

Total ablation time (in seconds) needed to achieve complete elimination of late abnormal ventricular activities (LAVAs) in myocardial scar.

Conditions Studied

Ventricular Tachycardia Ischemic Heart Disease Sustained VT

Interventions

  • DEVICE RFA Ablation
  • DEVICE PFA Ablation

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-06-16
Est. Completion 2028-12-31
Phase NA
Pasquale Santangeli

1 total trials

What NCT06891456 shows while recruiting

NCT06891456 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 287-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which RFA Ablation is the first listed.

NCT06891456 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06891456 about?

NCT06891456 is a clinical study titled "Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia". ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tach...

What is the current status of trial NCT06891456?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-06-16. Estimated completion is 2028-12-31.

What conditions does trial NCT06891456 study?

This clinical trial studies the following conditions: Ventricular Tachycardia, Ischemic Heart Disease, Sustained VT.

What interventions are being tested in trial NCT06891456?

The interventions under investigation include: RFA Ablation (DEVICE), PFA Ablation (DEVICE).

Who is sponsoring clinical trial NCT06891456?

This trial is sponsored by Pasquale Santangeli, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06891456 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ventricular Tachycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06891456's enrollment target sits among peer trials

40 23rd of 28 higher than 5 of 28 other Ventricular Tachycardia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ventricular Tachycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06891456

Source: ClinicalTrials.gov NCT06891456, the US trial registry maintained by the National Library of Medicine. NCT06891456 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.